The Effect of an Estrone D-Lactam Steroid Ester Derivative on Breast Cancer Cells and Its Predicted Binding Interactions With the Ligand Binding Domain of Estrogen Receptor-α
In order to further improve the toxicity profile and the anticancer effect of chlorambucil (CBL), we have synthesized a new estrone D-lactam steroidal ester of CBL (ESBL). The aim of this study was to investigate the in vitro activity of ESBL against primary breast carcinoma (BC) cells of operable tumors in comparison with CBL. Cells derived from fresh tumor sections that were obtained from 28 postmenopausal women with ductal BC were treated with CBL and ESBL. Apoptotic cells were distinguished from viable ones with flow cytometric methods. ESBL generated a significantly higher rate of cell apoptosis and cytotoxicity than CBL. ESBL cytotoxic effect demonstrated a significant positive weak to moderate dose-dependent correlation with the ER expression. ESBL produced antineoplastic activity superior to CBL on primary BC tumors in vitro. Moreover, a docking study on the binding interactions of ESBL with the ligand binding domain (LBD) of estrogen receptor-α (ERα) was investigated. ESBL was found to be positioned inside the binding cavity with its steroidal moiety, whereas the alkylating moiety protruded out of receptor's pocket.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Homo-aza-steroid alkylating esters
Document Type: Research Article
1st Department of Surgery, University of Athens, Laiko General Hospital, Athens, Greece
Lab of Medicinal Chemistry, Department of Pharmacy, University of Patras, Patras, Greece, 1st Department of Medical Oncology, “Metaxa” Cancer Hospital, Piraeus, Greece
Department of Cell Culture-Molecular Modeling & Drug Design, Symeonidio Research Center, Theagenio Cancer Hospital, Thessaloniki, Greece
Department of Pharmacognosy & Chemistry of Natural Products, School of Pharmacy, University of Athens, Athens, Greece
Lab of Medicinal Chemistry, Department of Pharmacy, University of Patras, Patras, Greece
Publication date: March 1, 2006
More about this publication?
Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.